TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25537365

Group type: EXPERIMENTAL
Intervention: rhTSH (100 mCi)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: rhTSH (70 mCi)
Number of subjects: 121

Group type: COMPARATOR
Intervention: LT4 withdrawal (100 mCi)
Number of subjects: 121

Group type: COMPARATOR
Intervention: LT4 withdrawal (70 mCi)
Number of subjects: 121
Study: 25539648

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate/emtricitabine (TDF‐FTC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21738093

Group type: EXPERIMENTAL
Intervention: Cortoss
Number of subjects: 256

Group type: COMPARATOR
Intervention: PMMA
Number of subjects: 256
Study: 20593942

Group type: EXPERIMENTAL
Intervention: Awareness of cervical cancer
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Knowledge of HPV virus as a risk factor
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Knowledge of multiple sexual partners as a risk factor
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Condom use among those aware of cervical cancer
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Awareness of Pap smear test
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Knowledge of Pap smear for cervical cancer detection
Number of subjects: 205
Study: 19005973

Group type: EXPERIMENTAL
Intervention: Soy isoflavones
Number of subjects: 2411

Group type: EXPERIMENTAL
Intervention: Tea consumption
Number of subjects: 2411

Group type: COMPARATOR
Intervention: Dietary fiber
Number of subjects: 2411
Study: 17162998

Group type: EXPERIMENTAL
Intervention: Pittsburgh Sleep Quality Index (PSQI)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Epworth Sleepiness Scale (ESS)
Number of subjects: 600
Study: 12514410

Group type: EXPERIMENTAL
Intervention: Atazanavir 200 mg once daily
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Atazanavir 400 mg once daily
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Atazanavir 500 mg once daily
Number of subjects: 420

Group type: COMPARATOR
Intervention: Nelfinavir 750 mg three times daily
Number of subjects: 420
Study: 10378564

Group type: EXPERIMENTAL
Intervention: MDI with small volume spacer (5 puffs, 450 microg albuterol)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nebulizer (2.5 mg albuterol)
Number of subjects: 30

Group type: COMPARATOR
Intervention: MDI port on right-angle adaptor (5 puffs, 450 microg albuterol)
Number of subjects: 30
Study: 8686821

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.1 mg.kg‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neostigmine 0.04 mg.kg‐1 with atropine 0.02 mg.kg‐1
Number of subjects: 0
Study: 1760834

Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin (NTG)
Number of subjects: 40
Study: 7471605

Group type: EXPERIMENTAL
Intervention: Indacrinone (−) enantiomer 10 mg with (+) enantiomer 0 mg (10/0)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Indacrinone (−) enantiomer 10 mg with (+) enantiomer 10 mg (10/10)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Indacrinone (−) enantiomer 10 mg with (+) enantiomer 20 mg (10/20)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Indacrinone (−) enantiomer 10 mg with (+) enantiomer 40 mg (10/40)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Indacrinone (−) enantiomer 10 mg with (+) enantiomer 80 mg (10/80)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Ticrynafen (T) 250 mg daily
Number of subjects: 65

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) 50 mg daily
Number of subjects: 65
Study: 31412818

Group type: EXPERIMENTAL
Intervention: Action 3:30R teaching assistant-led after-school intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Action 3:30R TA training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Action 3:30R intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Barriers to implementation
Number of subjects: 0
Study: 27610553

Group type: EXPERIMENTAL
Intervention: Smartphone application providing real-time feedback during resistance training
Number of subjects: 42
Study: 26860492

Group type: EXPERIMENTAL
Intervention: Conventional ultrasound therapy for 6 minutes at 1.5 Watt/cm2 dose with 1 MHz frequency for 15 days
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo ultrasound therapy
Number of subjects: 59
Study: 23320967

Group type: EXPERIMENTAL
Intervention: Intravenous epoetin (500 U/kg, 2 doses, 24 hours apart)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 21249383

Group type: EXPERIMENTAL
Intervention: Multi-sensor board (MSB)
Number of subjects: 57
Study: 19353740

Group type: EXPERIMENTAL
Intervention: Debio 025 600 mg/day + PEG IFN-alpha2a 180 microg/week
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Debio 025 1000 mg/day + PEG IFN-alpha2a 180 microg/week
Number of subjects: 0

Group type: COMPARATOR
Intervention: Debio 025 1000 mg/day (monotherapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: PEG IFN-alpha2a 180 microg/week (monotherapy)
Number of subjects: 0
Study: 17868953

Group type: EXPERIMENTAL
Intervention: High fat flavored cream cheese (orange or banana)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Low fat flavored cream cheese (orange or banana)
Number of subjects: 24
Study: 15497297

Group type: EXPERIMENTAL
Intervention: Computer-assisted injection system (Wand Plus)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional syringe technique
Number of subjects: 40
Study: 11556573

Group type: EXPERIMENTAL
Intervention: HA1 (500 mg three times daily for 3 days, total dose: 4,500 mg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: HA2 (500 mg three times daily for the first and the third day, total dose: 3,000 mg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: HA3 (500 mg three times for one day followed by 500 mg once daily for 7 days, total dose: 4,500 mg)
Number of subjects: 120
Study: 9577350

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate 1200 micrograms buccal spray
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 8
Study: 7909450

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 28
Study: 2905188

Group type: EXPERIMENTAL
Intervention: Chemotherapy (5‐fluorouracil (FU) and 1‐(2‐chloroethyl)‐3‐(4‐methylcyclohexil)‐1‐nitrosourea (Me‐CCNU) after surgery
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Chemo‐immunotherapy (FU, Me‐CCNU and levamisole) after surgery
Number of subjects: 235

Group type: COMPARATOR
Intervention: Surgery only
Number of subjects: 235
Study: 30753662

Group type: EXPERIMENTAL
Intervention: Standard care plus OH4L (Oral Health 4 Life)
Number of subjects: 718
Study: 30942789

Group type: EXPERIMENTAL
Intervention: French fries
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Home fries
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Hash browns
Number of subjects: 23

Group type: COMPARATOR
Intervention: Whole wheat pancake
Number of subjects: 23
Study: 29767924

Group type: EXPERIMENTAL
Intervention: Educational intervention based on the model of health beliefs (four training sessions in three months)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 90
Study: 26057204

Group type: EXPERIMENTAL
Intervention: Perampanel (PER)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 0
Study: 23782457

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) 1 g over 10 minutes followed by 1 g over 8 hours
Number of subjects: 20127

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 20127

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 20127
Study: 22275710

Group type: EXPERIMENTAL
Intervention: Negative viscosity training
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combined field training (augmented inertia with negative viscosity)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Null force field (control)
Number of subjects: 30
Study: 19781320

Group type: EXPERIMENTAL
Intervention: Biofragmentable anastomosis ring (BAR)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Manual suture
Number of subjects: 167
Study: 16309958

Group type: EXPERIMENTAL
Intervention: Ramelteon 4 mg
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Ramelteon 8 mg
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Ramelteon 16 mg
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Ramelteon 32 mg
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 15509406

Group type: EXPERIMENTAL
Intervention: Single-booklet questionnaire
Number of subjects: 3836

Group type: EXPERIMENTAL
Intervention: Single-sided questionnaire
Number of subjects: 3836

Group type: COMPARATOR
Intervention: Double-sided questionnaire
Number of subjects: 3836

Group type: COMPARATOR
Intervention: Multiple-booklet questionnaire
Number of subjects: 3836
Study: 11913275

Group type: EXPERIMENTAL
Intervention: 15% hydrogen peroxide in-office whitening system for 30 minutes
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 15% hydrogen peroxide in-office whitening system for 45 minutes
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 15% hydrogen peroxide in-office whitening system for 60 minutes
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combination of 15% hydrogen peroxide in-office treatment and 10% carbamide peroxide take-home treatment
Number of subjects: 24
Study: 9393426

Group type: EXPERIMENTAL
Intervention: Spectra-System implants (HA-coated cylinders)
Number of subjects: 2633

Group type: EXPERIMENTAL
Intervention: Spectra-System implants (titanium alloy baskets)
Number of subjects: 2633

Group type: COMPARATOR
Intervention: Bone quality 1 (BQ-1)
Number of subjects: 2633

Group type: COMPARATOR
Intervention: Bone quality 2 (BQ-2)
Number of subjects: 2633

Group type: COMPARATOR
Intervention: Bone quality 3 (BQ-3)
Number of subjects: 2633

Group type: COMPARATOR
Intervention: Bone quality 4 (BQ-4)
Number of subjects: 2633

Group type: COMPARATOR
Intervention: Clinical centers
Number of subjects: 2633
Study: 8200890

Group type: EXPERIMENTAL
Intervention: Single plate fixation with bone cement
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Double plating with bone cement
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Rush rods with bone cement
Number of subjects: 24

Group type: COMPARATOR
Intervention: Intact humeri
Number of subjects: 24

Group type: COMPARATOR
Intervention: Matched humeri with a defect
Number of subjects: 24
Study: 3295096

Group type: EXPERIMENTAL
Intervention: Ioxaglate
Number of subjects: 46

Group type: COMPARATOR
Intervention: Iopamidol
Number of subjects: 46

Group type: COMPARATOR
Intervention: Both Ioxaglate and Iopamidol
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Cardiac patients
Number of subjects: 46

Group type: COMPARATOR
Intervention: Non-cardiac patients
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 46
Study: 29329181

Group type: EXPERIMENTAL
Intervention: Retesting at 8 weeks
Number of subjects: 2253

Group type: COMPARATOR
Intervention: Retesting at 16 weeks
Number of subjects: 2253

Group type: COMPARATOR
Intervention: Retesting at 26 weeks
Number of subjects: 2253

Group type: EXPERIMENTAL
Intervention: All groups (8, 16, 26 weeks)
Number of subjects: 2253
Study: 26521660

Group type: EXPERIMENTAL
Intervention: Customized educational booklet and take-home educational materials
Number of subjects: 14

Group type: COMPARATOR
Intervention: Standard educational materials (control)
Number of subjects: 14
Study: 25428762

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg once weekly for 8 weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 90
Study: 23442031

Group type: EXPERIMENTAL
Intervention: Cyproheptadine
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control
Number of subjects: 51
Study: 20580422

Group type: EXPERIMENTAL
Intervention: Exenatide 2 mg injected once weekly
Number of subjects: 491

Group type: COMPARATOR
Intervention: Sitagliptin 100 mg oral once daily
Number of subjects: 491

Group type: COMPARATOR
Intervention: Pioglitazone 45 mg oral once daily
Number of subjects: 491
Study: 18211120

Group type: EXPERIMENTAL
Intervention: Dobutamine at a dose of 2.5 microg/kg/min
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Dobutamine at a dose of 5 microg/kg/min
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Dobutamine at a dose of 10 microg/kg/min
Number of subjects: 23
Study: 16630938

Group type: EXPERIMENTAL
Intervention: Active treatment (polymerized extract)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 12815493

Group type: EXPERIMENTAL
Intervention: Targeted intervention
Number of subjects: 1305

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1305
Study: 11483912

Group type: EXPERIMENTAL
Intervention: Fentanyl (50 to 100 microg)
Number of subjects: 825

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 825

Group type: COMPARATOR
Intervention: No intervention (observational group)
Number of subjects: 825
Study: 9605363

Group type: EXPERIMENTAL
Intervention: Risk score based on patient-related factors (gender, age, smoking status, history of PV or motion sickness, duration of anaesthesia)
Number of subjects: 1137
Study: 7847604

Group type: EXPERIMENTAL
Intervention: Nalmefene
Number of subjects: 1
Study: 3131904

Group type: EXPERIMENTAL
Intervention: Esberitox
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (no Esberitox)
Number of subjects: 50
Study: 31848068

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (2.0 mA)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS (2.0 mA)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sham tDCS (0.1 mA)
Number of subjects: 54
Study: 29623676

Group type: EXPERIMENTAL
Intervention: BRECONDA + usual care
Number of subjects: 222

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 222
Study: 28673384

Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy (TRT) for 24 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26330303

Group type: EXPERIMENTAL
Intervention: Diet
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Mainly exercise
Number of subjects: 243

Group type: COMPARATOR
Intervention: Control
Number of subjects: 243
Study: 23999955

Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 556

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 556
Study: 21143499

Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg kg(‐1) ideal body weight
Number of subjects: 20

Group type: COMPARATOR
Intervention: Atracurium 0.5 mg kg(‐1) total body weight
Number of subjects: 20
Study: 18332193

Group type: EXPERIMENTAL
Intervention: Adult child's reliance on instrumental support
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Adult child's reliance on expressive support
Number of subjects: 304
Study: 16550242

Group type: EXPERIMENTAL
Intervention: Family Meal Intervention (FMI)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Outpatient family-based therapy (without FMI)
Number of subjects: 12
Study: 14584714

Group type: EXPERIMENTAL
Intervention: Subgroup analyses in multiarmed clinical trials
Number of subjects: 0
Study: 10750628

Group type: EXPERIMENTAL
Intervention: Functional Insulin Treatment (FIT)
Number of subjects: 100
Study: 8956374

Group type: EXPERIMENTAL
Intervention: Nicotine transdermal patch (21 mg)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Placebo transdermal patch
Number of subjects: 211
Study: 1394752

Group type: EXPERIMENTAL
Intervention: Ketorolac (1 mg.kg‐1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Acetaminophen (10 mg.kg‐1)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Saline (0.1 ml.kg‐1)
Number of subjects: 90
Study: 30077043

Group type: EXPERIMENTAL
Intervention: Higher average rating of surgeons
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Experience of surgeons
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Trustworthiness
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Negative comments on professional competence
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Experience match
Number of subjects: 250
Study: 29769831

Group type: EXPERIMENTAL
Intervention: 5 g Specific Collagen Peptides (SCP)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 5 g Placebo (Maltodextrin)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Follow-up after 3 months
Number of subjects: 50
Study: 26811431

Group type: EXPERIMENTAL
Intervention: Indoor residual spraying (IRS) with α‐cypermethrin plus standard of care environmental management (SoC‐EM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-lasting insecticide-treated nets (LLINs) plus standard of care environmental management (SoC‐EM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care environmental management (SoC‐EM)
Number of subjects: 0
Study: 24631058

Group type: EXPERIMENTAL
Intervention: Head Elevated Ramped Position
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control - horizontal with a small pillow under the head
Number of subjects: 60
Study: 22108101

Group type: EXPERIMENTAL
Intervention: Laser-sintered Co-Cr (LS) with Ketac Cem Plus (KC)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vacuum-cast Pd-Au (CP) with Ketac Cem Plus (KC)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vacuum-cast Co-Cr (CC) with Ketac Cem Plus (KC)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Laser-sintered Co-Cr (LS) with Panavia F 2.0 (PF)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vacuum-cast Pd-Au (CP) with Panavia F 2.0 (PF)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vacuum-cast Co-Cr (CC) with Panavia F 2.0 (PF)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Laser-sintered Co-Cr (LS) with RelyX Unicem 2 Automix (RXU)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vacuum-cast Pd-Au (CP) with RelyX Unicem 2 Automix (RXU)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vacuum-cast Co-Cr (CC) with RelyX Unicem 2 Automix (RXU)
Number of subjects: 30
Study: 21660774

Group type: EXPERIMENTAL
Intervention: First-year student physical activity and action-planning brochure
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Canada's Physical Activity Guide (CPAG)
Number of subjects: 255

Group type: COMPARATOR
Intervention: No-intervention control group
Number of subjects: 255
Study: 17561977

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 0
Study: 16089139

Group type: EXPERIMENTAL
Intervention: Intra-articular injection of Sodium hyaluronate (SH) plus external application of Sanhua ointment (SHO)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Intra-articular injection of Sodium hyaluronate (SH)
Number of subjects: 112
Study: 12145036

Group type: EXPERIMENTAL
Intervention: 0.9% saline (NS) solution
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lactated Ringer's (LR) solution
Number of subjects: 30
Study: 9933262

Group type: EXPERIMENTAL
Intervention: Infarct volume measured by operator‐assisted computerized planimetry in patients with visible new supratentorial infarcts (132 patients)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Infarct volume correlations with clinical outcome scales
Number of subjects: 191
Study: 7483543

Group type: EXPERIMENTAL
Intervention: Gastrocepine
Number of subjects: 72

Group type: COMPARATOR
Intervention: H2-blockers
Number of subjects: 72
Study: 2249121

Group type: EXPERIMENTAL
Intervention: Cephalosporin antibiotic prophylaxis
Number of subjects: 196

Group type: COMPARATOR
Intervention: Antiseptic lubricating jelly
Number of subjects: 196
Study: 7028069

Group type: EXPERIMENTAL
Intervention: Inoculation with an autologous irradiated suspension of tumour cells combined with a small dose of C. parvum given intradermally during convalescence
Number of subjects: 95

Group type: COMPARATOR
Intervention: Routine follow-up
Number of subjects: 95
Study: 31787389

Group type: EXPERIMENTAL
Intervention: Apple Watch (AW)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Fitbit (FB)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both devices (AW and FB)
Number of subjects: 32
Study: 31404850

Group type: EXPERIMENTAL
Intervention: Mindfulness‐Oriented Recovery Enhancement (MORE)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 30
Study: 28121650

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Clerkships as usual (CAU)
Number of subjects: 167
Study: 25291318

Group type: EXPERIMENTAL
Intervention: Diabetes self-management education plus nurse case management
Number of subjects: 71

Group type: COMPARATOR
Intervention: Diabetes self-management education only
Number of subjects: 71
Study: 23810691

Group type: EXPERIMENTAL
Intervention: Behavioral interventions (counseling on weight loss, healthy diet, and exercise)
Number of subjects: 481
Study: 20946227

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 18551295

Group type: EXPERIMENTAL
Intervention: Supplementation with 12 mg lutein and 1 mg zeaxanthin once per day (Ocuvite lutein) for 6 months
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (no dietary supplement)
Number of subjects: 108
Study: 17645482

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg b.i.d.
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: High-dose pantoprazole (80 mg + 8 mg/h)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Pantoprazole 40 mg q.d.
Number of subjects: 52
Study: 15738857

Group type: EXPERIMENTAL
Intervention: Individual cognitive-behavioral therapy (CBT)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Self-help cognitive-behavioral therapy (CBT)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral therapy (CBT)
Number of subjects: 84
Study: 11158186

Group type: EXPERIMENTAL
Intervention: Marimastat (an orally bioavailable analogue of batimastat)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Col-3 (a nonantibiotic chemically modified tetracycline)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonpeptidic MMP inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tetracyclines
Number of subjects: 0
Study: 9812649

Group type: EXPERIMENTAL
Intervention: Salvia Miltiorrhiza Composita (SMCo)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no SMCo)
Number of subjects: 40